Comparative Pharmacology
Head-to-head clinical analysis: NITROMIST versus NITRONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROMIST versus NITRONAL.
NITROMIST vs NITRONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.
None Documented
None Documented
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal elimination half-life is 1-4 minutes (due to rapid hepatic metabolism via glutathione S-transferase). Clinical context: necessitates continuous IV infusion for sustained effect.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Renal: ~60% as inactive metabolites; fecal: ~35% via bile; unchanged drug: <1%.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator